The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

December 7, 2021 • By Jeffrey Curtis, MD, MS, MPH

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Although the trial was underpowered because recruitment was halted prematurely, with the COVID-19 pandemic offered as a partial explanation, it nevertheless offers hope that non-traditional RA therapies may confer benefit to slow or even halt the devastating manifestations of ILD that affect many RA patients.

You Might Also Like
  • COVID-19 Vaccination for Immunosuppressed Patients: From Guidance to Advocacy
  • New Findings on COVID-19 Vaccination, Race & More Shared in 1st Plenary Session
  • COVID-19 Vaccination Induces T Cell Response in Patients Treated with Rituximab
Explore This Issue
January 2022

Abstract 0982: B cells repertoire repartition predicts response to methotrexate at 6 and 12 months in naïve RA: A machine learning driven approach11

Research by Najm A, et al.

Enthusiasm abounds to use automated, data-driven approaches to predict treatment response coupled with advances in precision medicine. However, in RA, many datasets are too small for machine learning or artificial intelligence to be effectively used, or are conducted with minimal attention to replication and validation—an essential feature of any machine learning-based approach.

Peripheral blood leucocytes from early RA patients in the SERA cohort had their B cell repertoire measured as a predictive marker to response to MTX. Baseline levels of circulating IgD+ B cells clones were more frequent in responders compared with non-responders (P=0.004), whereas IgA1+ and IgA2+ clones tended to be more frequently represented in non-responders (P=0.069 and P=0.001 respectively). A gradient boosting statistical model showed the response to MTX could be predicted with a sensitivity of 78%, specificity of 79% and an area under the curve of 0.88, consistent with good discrimination.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Although further replication is warranted, this study is one of the first immunology-based prediction model for MTX and suggests that advanced machine learning methods may be useful to support precision medicine in RA. Those predicted to be non-responders to MTX may be targeted to start combination therapy, rather than MTX monotherapy, when RA therapies are first prescribed.


Jeffrey Curtis, MD, MS, MPH, is a professor of medicine and holds the Marguerite Jones Harbert—Gene Ball Endowed Professorship in Rheumatology and Immunology, in the Division of Clinical Immunology & Rheumatology at the University of Alabama at Birmingham (UAB). He is board certified in both rheumatology and clinical informatics. He is the co-director of the UAB Pharmacoepidemiology and Pharmacoeconomics Research (PEER) Unit.

In 2012, he was awarded the Henry Kunkel Young Investigator Award by the ACR) and was accepted into the American Society for Clinical Investigation (ASCI) in 2016. The evaluation of the efficacy, comparative effectiveness, and safety of the medications used to treat RA and spondyloarthritis are among Dr. Curtis’s research interests.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

He served on the Core Expert Panel for the ACR’s 2008, 2012 and 2015 Recommendations for the Use of Nonbiologic and Biologic Disease Modifying Antirheumatic Drugs in RA. He was the deputy director for a collaborative project between the U.S. Food & Drug Administration (FDA), the Agency for Healthcare Research and Quality (AHRQ) and a number of academic centers studying the safety of biologic agents using multiple, pooled national data sources.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 7 8 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, Research Reviews, Rheumatoid Arthritis Tagged With: ACR Convergence 2021, ACR Convergence 2021 – RAIssue: January 2022

You Might Also Like:
  • COVID-19 Vaccination for Immunosuppressed Patients: From Guidance to Advocacy
  • New Findings on COVID-19 Vaccination, Race & More Shared in 1st Plenary Session
  • COVID-19 Vaccination Induces T Cell Response in Patients Treated with Rituximab
  • COVID-19 Vaccination Strategies Suggested for Patients on Anti-Rheumatic Immunosuppressive Therapy

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)